Video

Dr Sumit Subudhi Discusses Immune Checkpoint Inhibitors in Prostate Cancer

In prostate cancer, we're using combinations by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, MD Anderson Cancer Center.

In prostate cancer, combination therapies are being used to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, Cancer Medicine, MD Anderson Cancer Center.

Transcript (slightly modified)

Prostate cancer has had lower response rates to single-agent immune checkpoint inhibitors than other cancers. How are you working towards understanding who will have the best response to these inhibitors?

It’s been a real struggle to get the response we see in malignancies such as melanoma, kidney, and bladder. What we’re starting to understand is that the prostate cancer tumor microenvironment is just really an immunosuppressive 1, and so the strategies we’re using now is using combinations, and rational combinations, by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy.

So, for example we’ve completed a trial where we were doing ipilimumab plus anti- PD-1, and the reason for that was after giving 2 doses of ipilimumab, we found that the tumor microenvironment upregulates both PD-1 and PD-L1, so by doing the combination, we should see better responses, and so far it looks like the early signals show that. We’re getting better response, but not as well as we see in melanoma.

What we’re going to have to do is find out who are these patients that actually respond so that we can enrich that population and then also better understand why the other patients are not responding.

Related Videos
Drs Lillian L. Siu and Matthew G. Vander Heiden
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Kimberly Westrich, MA, chief strategy officer, NPC
Marla Black Morgan, MD, Phoebe Neurology Associates
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo